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Abstract
Background: Recent attention has focused on strategies to combat the forecast epidemic of type-2 diabetes
(T2DM) and its major vascular sequelae. Metabolic syndrome (MetS) comprises a constellation of factors that
increase the risk of cardiovascular disease (CVD) and T2DM. Our study aims to develop a structured self-
management education programme for people with MetS, which includes management of cardiovascular and
diabetes risk factors, and to determine its impact. This paper describes the rationale and design of the TRIMS study,
including intervention development, and presents baseline data.
Methods: Subjects recruited from a mixed-ethnic population with MetS were randomised to intervention or
control arms. The intervention arm received structured group education based on robust psychological theories
and current evidence. The control group received routine care. Follow-up data will be collected at 6 and 12
months. The primary outcome measure will be reversal of metabolic syndrome in the intervention group subjects
compared to controls at 12 months follow-up.
Results: 82 participants (44% male, 22% South Asian) were recruited between November 2009 and July 2010.
Baseline characteristics were similar for both the intervention (n = 42) and control groups (n = 40). Median age
was 63 years (IQR 57 - 67), mean waist size 106 cm (SD ± 11), and prescribing of statins and anti-hypertensives was
51% in each case.
Conclusion: Results will provide information on changes in diabetes and CVD risk factors and help to inform
primary prevention strategies in people with MetS from varied ethnic backgrounds who are at high risk of
developing T2DM and CVD. Information gathered in relation to the programme’s acceptability and effectiveness in
a multi-ethnic population would ensure that our results are widely applicable.
Trial registration: The study is registered at ClinicalTrials.gov, study identifier: NCT01043770.
Background
The predicted global increase in type-2 diabetes (T2DM)
and cardiovascular disease (CVD), and associated morbid-
ity and mortality, are a growing public health burden [1,2].
This is largely due to rising levels of obesity, and sedentary
lifestyles. Additionally, the disease burden in certain ethnic
groups such as South Asians (SAs) is significantly higher
than for White Europeans (WEs) [3,4]. Strategies to
reduce the development of CVD and T2DM in high risk
individuals are a priority.
People who are centrally obese often have a clustering of
additional cardiovascular and diabetes risk factors such as
elevated blood pressure, dyslipidaemia and impaired glu-
cose metabolism, which have been linked to insulin resis-
tance and collectively termed metabolic syndrome (MetS)
[5,6]. Prevalence estimates for MetS vary widely between
populations [7]. It has previously been suggested that
between 13 - 30% of people in developing countries have
MetS [8] and around 35% in high-income nations such as
the US [9]. Additionally, the prevalence of MetS increases
with age, is higher in socio-economically disadvantaged
groups [10,11], and shows ethnic differences [12]. UK data
suggest that approximately 30 - 34% of adults aged 40 to
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any medium, provided the original work is properly cited.75 years have MetS [13], and this number is likely to rise
as lifestyles continue to become increasingly inactive.
Lack of a consensus definition and concerns about
whether the risk conveyed by the syndrome as a whole
exceeds the total risk associated with individual compo-
n e n t s ,h a v el e dt od e b a t ea b o u tt h ep r o g n o s t i cs i g n i f i -
cance of MetS [14]. Its usefulness in clinical practice
compared to existing tools such as the Framingham CVD
risk score [15,16], has also been questioned. However,
MetS is linked to an increased risk of developing both
CVD and T2DM. Evidence indicates that people with
MetS are approximately twice as likely to have CVD
(incident disease or event) [17], and are between 3.5 to 5
times as likely to develop T2DM [18]. Furthermore,
MetS is of great importance to public health as it pre-
cedes T2DM and CVD by several years. People with
MetS could, therefore, be an important group to target
for primary prevention of T2DM and CVD [14,19]. Addi-
tionally, MetS could be a useful concept for healthcare
professionals and patients to focus on when addressing
the health risks associated with abdominal obesity [20]. It
is therefore essential to develop a pragmatic early inter-
vention that can be easily implemented to a large number
of people in primary care.
A recent meta-analysis suggests that intensive lifestyle
programmes targeted at people with pre-diabetes, who are
at high risk of T2DM, are effective in reducing the inci-
dence of diabetes by more than 50% [21]. However, target-
ing dysglycaemia in isolation may not be the best approach
if the ultimate aim is to reduce the rate of cardiovascular
complications. Evidence from clinical trials is limited
regarding the effectiveness of strategies aimed at primary
prevention of T2DM and/or CVD in people with MetS.
Research is therefore needed into the efficacy of lifestyle
interventions for primary prevention of T2DM and CVD
that can be applicable to multi-ethnic populations with
MetS.
The aim of The Reversal Intervention for Metabolic
Syndrome (TRIMS) study is to investigate the hypothesis
that delivery of a group self-management education pro-
gramme designed to encourage lifestyle changes in indivi-
duals identified with MetS would be a feasible, acceptable,
and effective strategy for primary prevention of CVD and
T2DM. Specific objectives of the study are to: a) develop
an evidence based education programme to improve cardi-
ovascular risk and dysglycaemia in people with MetS in
primary care; b) determine the impact of attending an
education programme on features of MetS and quality of
life after 12 months of follow-up; and c) assess acceptabil-
ity, uptake, and feasibility of implementing a group self-
management education programme in an ethnically
diverse population of individuals with MetS.
Development, evaluation and implementation of the
TRIMS intervention is guided by the most recent
Medical Research Council (MRC) Framework for devel-
oping and evaluating complex interventions [22]. This
article outlines the development, piloting and initial
exploratory evaluation of the study intervention. Addi-
tionally, the paper describes the design of the main
TRIMS study, including the methods used for delivering
the trial intervention and for carrying out a definitive
evaluation. Baseline data are also reported.
Methods
Study design
The TRIMS study was designed as a single-centre, 2
arm, parallel, 12 month randomised controlled trial
(RCT) that compared the effectiveness of structured
group lifestyle education (intervention) with usual care
(control). Prior to commencing the main trial, an in-
depth development and feasibility phase was carried out
to ensure that the design of the intervention was appro-
priate for people with MetS.
1. Development and feasibility phase
Curriculum development We adapted an existing group
lifestyle education programme (Let’s Prevent) which was
originally developed for people with pre-diabetes [23].
The style, content and process of this programme draw
on a range of concepts from health psychology and edu-
cation [24-26] (see Table 1) and its philosophy is centred
on patient empowerment. The key nutritional and physi-
cal activity messages are based on evidence from previous
diabetes prevention trials [27-29]. Permission to adapt
the pre-diabetes programme was granted by the DES-
MOND collaborative [30]. Using this curriculum as a fra-
mework, the TRIMS curriculum was revised to make it
more suitable for people with MetS, who may or may not
be dysglycaemic, and include additional emphasis on
management of cardiovascular risk.
A multi-faceted approach was adopted to inform the
detailed development of the TRIMS education pro-
gramme. Firstly, existing evidence regarding the effective-
ness of lifestyle interventions for reversing metabolic
syndrome was collated by conducting a systematic review
and meta-analysis [31]. Secondly, currently published
guidelines and recommendations were reviewed, some
specifically for MetS and others providing more general
guidance related to management of CVD risk, and diet
and nutrition [5,6,32-39]. A combined approach was
used to ensure that the lifestyle behaviour modifications
recommended by the TRIMS programme were evidence
based and also in line with current UK practice guidance.
The evidence to support specific lifestyle elements of the
programme is outlined in Table 2.
Subsequently, an initial curriculum was developed by a
multi-disciplinary team. Additional resources were also
developed including a handbook for patients to reinforce
what they had learnt on the course and use as a resource
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were: to increase knowledge and understanding of MetS,
including raising awareness of possible future health risk
and of potential prevention strategies; to enhance self-
efficacy and self-regulatory skills in order to promote
healthy lifestyle behaviours. The key behavioural goals
the programme aimed to promote included: 1) increasing
physical activity, ≥ 45 minutes of moderate intensity
activity (or an extra 4,500 steps) per day; 2) losing weight
(reducing waist size), a reduction of between 5 - 10% of
initial body weight through increasing physical activity
and/or reducing calorie intake; 3) increasing dietary fibre
consumption, particularly wholegrains, legumes, fruits
and vegetables; 4) reducing consumption of saturated
fats; 5) reducing salt intake; 6) increasing intake of
omega-3 fatty acids; and 7) smoking cessation. However,
despite suggested targets, the emphasis of the programme
was on enabling participants to set their own realistic
personalised goals for behaviour change.
Piloting Permission to pilot the education sessions within
primary care was obtained from Leicester City Primary
Care Trust. One large general practice in the city was sub-
sequently approached and agreed for their patients to be
involved. From this practice a sample of patients who
were on the hypertension register and also met the criteria
for MetS were sent a letter and information sheet by their
general practitioner (GP), identifying them as having MetS
and inviting them to attend the education sessions. This
was followed-up by a telephone call from their GP
approximately one week later.
The structured group education programme was deliv-
ered as two 3-hour, afternoon sessions held 2 weeks
apart, at the health centre where the GP practice was
based. Two experienced health educators, a nurse and a
dietician, led the sessions. The sessions were designed to
encourage participation and included games/activities.
Participants were also supported to identify personal
risk factors that they wished to change and to formulate
a self-management plan. As part of the education ses-
sions the participants were provided with a pedometer
and activity logbook to use as motivational tools, and a
handbook to use during sessions and then take away as
a resource in the future.
A range of methods was used to evaluate the educa-
tion sessions and collect feedback. These included
observations recorded during the sessions by an experi-
enced researcher, reflections from the two educators
leading the programme, and semi-structured interviews
conducted by telephone with volunteers who had
attended the education sessions. Qualitative data from
these sources were collated using Framework Charting
[40].
Table 1 Main theories underpinning the structured group education self-management approach
Theory Key elements
Common sense model People tend to conceptualise a health threat/problem according to 5 domains:
Identity; Cause; Timeline; Consequences; Control/cure
Important to elicit these beliefs as thought to influence coping and self-care behaviour
Influenced by social and cultural factors
Health information needs to be aimed at targeting all 5 domains. If not:
Individual is likely to acquire the missing information from another source
Risk of forming spurious health beliefs
Could negatively impact subsequent coping behaviour
Dual process theory Systematic processing of information is encouraged
Individual’s are encouraged to take an active role in their learning and work things out and ask questions
The educator does not lecture or dictate but uses open questions to elicit information
Active learning requires recipient to make more effort. However:
Results in individual’s making a stronger link between theoretical concepts and their personal situation
Attitude change generally lasts longer when produced by systematic processing
Social cognitive (learning) theory Behavioural change is influenced by an individual’s:
Sense of control or perceived self-efficacy
Expectancies about outcomes of personal actions
Social modelling of knowledge and competencies
People learn from interaction with others.
Helps a person to realise what they already know
Cultivates new competencies
Instils behavioural outcome expectations
The educator supports individuals to put the elements in place and move forward
References: Common sense model [26]; Dual process theory [25]; Social cognitive (learning) theory [24].
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of the education programme, people found it difficult to
comprehend MetS as it was an unfamiliar concept.
However, with repeated explanations and reinforcement
throughout the programme, the sessions helped indivi-
duals to understand the syndrome, including the role of
abdominal obesity (waist size) and possible future health
risks. This was something people said that they valued
and it enabled them to focus on their own personal risk.
Key messages that people felt they had taken away from
the sessions included: making healthier food choices,
reading food labels and using a pedometer and log-book
to help increase activity levels. For some parts of the
curriculum, some individuals expressed a preference for
a more direct approach, with the educator talking more
and less group discussion, specifically for topics with
which people were less familiar. Overall, learning as part
of a group was favoured by individuals as they felt they
benefitted from the questionst h a to t h e rp e o p l ea s k e d
and the sharing of experiences.
Modifications to the intervention as a result of pilot-
ing Findings from the pilot of the intervention were
used to help refine the curriculum, resources and style
of delivery of the programme. The content and structure
of the final TRIMS education programme used for the
main trial is outlined in Table 3. Revisions made after
piloting included changes to the introduction section at
the start of the education programme, to ensure that
educators made participants aware of the non-didactic
approach that would be used. This included emphasising
the benefits of the style of delivery to be used, including
group participation and facilitation of learning through
the use of open questions, games and activities. This
reinforced explanations given in a pre-course booklet
that introduced people to what they could expect when
they attended the group sessions. Another revision to
the programme involved simplifying the way in which
MetS was explained. The part of the curriculum related
to understanding MetS, particularly the sections focus-
ing on how the body uses and stores energy from food
(fats and carbohydrates) and the role of insulin resis-
tance, was amended. Additional prompts were also
added, to help educators to link explanations about
MetS to any prior perceptions and beliefs that partici-
pants may have shared as part of the patient story sec-
tion. The accompanying resources were also modified.
Additionally, in response to feedback, a food diary was
added to the participant handbook so that people could
optionally record their daily food intake. This comple-
mented the physical activity logbook already provided.
Table 2 Key lifestyle elements included in the TRIMS education programme
Modifiable lifestyle
factors
Key lifestyle elements Source of evidence
MetS systematic
review
MetS specific guidelines &
recommendations
Other guidelines &
recommendations
PHYSICAL ACTIVITY Increase physical activity ✓✓ ✓
WEIGHT/WAIST SIZE Sustained weight loss ✓✓ ✓
Moderate calorie restriction ✓✓ ✓
DIETARY FACTORS Dietary consumption:
Fibre Increase wholegrains (reduce refined
carbohydrates)
✓✓ ✓
Increase legumes ✓✓ ✓
Increase fruit and vegetables ✓✓ ✓
Fats Moderate reduction in total fat ✓✓ ✓
Reduce saturated fat ✓✓ ✓
Increase mono-unsaturated fat ✓✓ ✓
Omega-3 Increase fish/oily fish ✓✓ ✓
Salt Reduce salt ✓✓ ✓
Alcohol Alcohol in moderation ✓✓ ✓
SMOKING Cessation of smoking ✓✓ ✓
References: MetS systematic review [31]; MetS specific guidelines & recommendations [5,6,37,38]; Other guidelines & recommendations [32-36].
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PART 1 - First week Overview of the main aims
and activities
Theory
A: Introduction and Housekeeping
(5 minutes)
To inform participants of the aims of the course, main topics to be covered, and
the style of delivery
B: The Patient Story (20 minutes)
1) Names
2) How did you find out you had metabolic
syndrome
3) What do you think it is? Causes?
4) What will it mean for my health?
Treatments?
5) Have you a question?
To elicit an individual’s experiences, perceptions and health beliefs
Participants are encouraged to share their experiences and beliefs with the rest of
the group, and identify any questions they have
Common sense
model
C: Metabolic Syndrome and Insulin
Resistance
1) Understanding metabolic syndrome (55
minutes)
￿ Energy from food - food groups
￿ Healthy metabolism - energy used/stored
￿ Abdominal obesity and insulin resistance
￿ Cholesterol
￿ Blood pressure
2) How does metabolic syndrome affect
me? (40 minutes)
￿ Understanding your personal results
￿ Causes
￿ Reversing metabolic syndrome and
reducing the risk of T2DM and CVD
To help participants understand what metabolic syndrome is, possible causes,
what it means to their health, and possible ways to reduce their future health risk
Participants are helped to work through what is happening in the body with
metabolic syndrome, complete their own personal health profile, and consider
how they were identified as having metabolic syndrome
Common sense
model
Dual process
theory
D: Physical Activity (40 minutes)
1) Benefits
2) Recommendations
3) Measuring activity
4) Barriers and facilitators
To facilitate exploration of the recommendations and benefits of physical activity,
and possible barriers
Participants are:
Encouraged to consider ways to increase their activity levels (including their own
personal activity targets)and how this could reduce future health risk
Shown and discuss how they can use a pedometer and logbook as a motivational
tool and encouraged to go away and use them before their next session
Common sense
model
Dual process
theory
Social cognitive
(learning) theory
E: How Am I Doing Participants are encouraged to reflect on the main messages so far and start to
think about possible lifestyle changes
Social cognitive
(learning) theory
PART 2- Second week
F: Reflections (5 minutes) Participants are encouraged to reflect on issues that have come up and share
these with the group
Social cognitive
(learning) theory
￿ G: Weight management and Food
Choices (1) (35 minutes)
1) Factors influencing food choices
2) Monitoring weight/shape
3) Energy balance
4) Losing weight/reducing waist size
5) Food messages
￿ Fat, alcohol, fruit and vegetables
To help participants explore factors involved in weight management, and consider
food choices.
Participants are:
Encouraged to consider practical ways to lose weight/reduce waist size
Helped to work through what factors can cause changes in weight and which
foods are higher sources of calories
Shown and discuss how they could use a food diary to record what they eat and
drink and identify possible changes they could make.
Common sense
model
Dual process
theory
Social cognitive
(learning) theory
H: Food Choices (2) (75 minutes)
1) Types of fats
2) Omega-3
3) Fibre
4) Salt
5) Making healthier food choices
To facilitate exploration of the recommendations and benefits of making healthier
food choices, and how these relate to metabolic syndrome and individual risk
factors
Participants are encouraged to consider ways to make healthier food choices
(including reading food labels) and how this could reduce future health risk
Common sense
model
Dual process
theory
Social cognitive
(learning) theory
I: Metabolic Syndrome Self-Management
Plan (40 minutes)
1) Additional risk factors - smoking,
depression
2) Behaviour change
3) Identifying personal risk factors &
completing an action plan
To help participants to identify a behavioural goal they can aim for to improve
their risk profile/reverse metabolic syndrome, and make a realistic plan of action
for this behaviour change
Participants are helped to:
Identify things they want to change based on their personal health profile,
Explore possible options utilising information from previous sessions
Identify personal barriers
Develop their own personal action plan
Social cognitive
(learning) theory
J: Questions and Future Care (10 minutes) To ensure that all questions previously raised by participants have been answered
fully, and that they know how to access ongoing care and support
Common sense
model
Throughout the sessions a combination of open questions, analogies, visual aids, games, activities and a personal handbook are used by the educators to assist
participants learning. Each week included a 15 minute break.
References: Common sense model [26]; Dual process theory [25]; Social cognitive (learning) theory [24]
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Participant recruitment Local ethics and research gov-
ernance approvals were obtained prior to conducting the
main TRIMS RCT. General practices (in Leicestershire,
UK) who were already taking part in local population
based diabetes screening studies [41-43] were approached
to participate. Potential participants aged 40 - 74 years,
from volunteer practices, were then recruited by postal
invitation using two different recruitment strategies.
Firstly, eligible people identified as having MetS (Interna-
tional Diabetes Federation (IDF) definition [6]) according
to their previous screening results, were sent a postal
invitation via their GP. Secondly, people who had con-
sented to be approached with details of other research
studies, when they participated in a screening study, and
who met the inclusion criteria were sent a letter of invita-
tion by the principal investigator of the screening study.
Exclusion criteria included previous history of T2DM or
CVD; pregnancy and/or breast feeding; life-limiting term-
inal illness; lack of capacity to give informed consent;
being housebound or residing in a nursing/care home;
and inability to understand, speak and read English.
Respondents were asked to attend for an initial appoint-
ment having fasted overnight for at least 8 hours. Written
informed consent was obtain e df r o mv o l u n t e e r sb ya
research nurse prior to carrying out any tests or measure-
ments. Participants underwent a 75 g oral glucose toler-
ance test (OGTT) [44], and had additional demographic
and bio-medical data collected in a standardised way,
according to the schedule in Table 4. Data collected
included measurements to confirm eligibility and MetS
status; however, if relevant blood tests for glucose and
lipids had been conducted for screening within the last 3
months these were not repeated and the initial screening
values were used as the baseline values.
Randomisation Following their baseline appointment,
eligible volunteers were randomised to either the study
intervention arm (routine care plus TRIMS group educa-
tion programme) or control arm (routine care) using com-
puter-generated block randomisation. The researcher who
held the randomisation sequence had no involvement with
the recruitment of participants or baseline data collection.
Blinding of participants was not possible due to the nature
of the study. Participants were informed of their group
allocation by a letter sent in the post and volunteers GPs
were also provided with this information. People in the
intervention group were informed that they would be
given their bio-medical results as part of the TRIMS edu-
cation and the control group were asked to contact their
GP if they wanted any information about their results.
Delivery of the TRIMS intervention
Intervention group participants were contacted by tele-
phone within 1 - 2 weeks of their baseline assessment
and invited to attend the TRIMS education programme
within the following 2 months. The education sessions
were held Monday to Saturday, at various local commu-
nity venues and consisted of 6 hours of contact time
spread over two 3 hour sessions, held approximately 2
weeks apart. Participants were also invited to bring a
friend or relative for both social and practical support.
Two trained educators (AJD plus another nurse or a
dietician) facilitated the groups. The approximate pro-
portions of the curriculum devoted to specific topics are
outlined in Table 3. In addition to attending the initial
group education, at 6 months people will be given the
option of receiving additional support from an educator
(AJD), via the telephone, to answer any queries and con-
cerns and to help participants update their self-manage-
ment education resources.
Primary and secondary outcomes
The primary outcome is reversal of MetS according to
the IDF criteria in the intervention group compared to
the control group, after 12 months of follow-up. Taking
into account the ethnic diversity within our target popu-
lation, the IDF criteria were chosen in preference to the
National Cholesterol Education Panel (NCEP) definition
due to the provision of ethnic specific cut points for
waist circumference and central obesity (Table 5). Sec-
ondary outcomes compared at baseline versus 12
months, and for the intervention group versus the con-
trol group, see Table 4, include changes in: i) the preva-
lence of MetS according to NCEP criteria; ii) individual
components of the MetS (fasting plasma glucose, trigly-
cerides, high density lipoprotein cholesterol (HDL),
blood pressure, waist circumference), and 2 hour
glucose.
Data collection and assessment of outcomes
R o u t i n el a b o r a t o r ym e t h o d swere used for all biochem-
ical measurements. Serum total cholesterol, HDL cho-
lesterol, and triglycerides; plasma fasting and 2-hour
glucose; and urine albumin and creatinine, were mea-
sured using a Siemens Adiva 2400 analyser (Siemens
Healthcare Diagnostics, Camberley, UK). Glycated hae-
moglobin (HbA1c) was measured using a Tosoh G7
analyser (Tosoh Bioscience Ltd, Redditch, UK). Low
density lipoprotein cholesterol (LDL) was estimated
using the Friedewald equation[45]. If participants gave
consent, additional blood was taken at baseline (and 12
months) for measurement of bio-markers that are linked
to MetS (high-sensitivity- C-reactive protein (hs-CRP),
adiponectin and insulin)[46]. After processing, the
serum for bio-markers was stored in aliquots at -80°c
and these samples will be analysed as a single batch at
the end of the study.
Resting blood pressure was measured using an Omron
automatic blood pressure monitor, (Omron Healthcare
UK Ltd) and a mean value was calculated from the last 2
measurements in a series of three. Waist circumference
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iliac-crest, in the mid-axillary line, over minimal clothing
and at the end of expiration, and was recorded to the
nearest mm. Hip circumference was measured at the
widest point over the buttocks and to the nearest mm.
Weight in light clothing and no shoes was recorded to
the nearest 0.1 kg using a digital scale, and height to the
nearest cm using a stadiometer and with head placed in
Table 4 Data collection schedule and outcome measures
Collected by research nurse Baseline 6
months
12
months
Bloods & biomedical data
FPG ✓✓✓
2 hour glucose ✓✓✓
HbA1c ✓✓✓
Total cholesterol ✓✓✓
HDL ✓✓✓
Triglycerides ✓✓✓
Albumin:creatinine ratio (urine) ✓✓✓
Blood pressure ✓✓✓
Waist circumference ✓✓✓
Hip circumference ✓✓✓
Height ✓✗✗
Weight ✓✓✓
Medical history ✓✓✓
Current medication ✓✓✓
Smoking status ✓✓✓
Biomarkers
Insulin, Hs-CRP, Adiponectin ✓✗✓
Demographic details
Age ✓✗✗
Sex ✓✗✗
Ethnicity
(adapted from classification used for 2001 UK census)
✓✗✗
Current employment status
(working, retired, unemployed, long term sick/disabled, never worked, other)
✓✗✗
Education
(age finished full time education, & highest level of qualification held)
✓✗✗
Socio-economic classification
(NS-SEC-5-Class) [57]
✓✗✗
Deprivation score
(IMD score, 2007)[58]
✓✗✗
Self-reported data
Questionnaires
Physical activity
IPAQ (short form) [47]
✓✓✓
Anxiety & depression
HADS [48]
✓✓✓
Quality of life
EQ-5D [49]
✓✓✓
Dietary habits
DINE [50]
✓✓✓
General self-efficacy
GSE [51]
✓✓✓
Other
Ambulatory activity ✓✓✓
Abbreviations: FPG (fasting plasma glucose); HbA1c (glycated haemaglobin); HDL (high density lipoprotein cholesterol); NS-SEC-5-Class (National Statistics Socio-
economic Classification 5-Class version); IPAQ (International Physical Activity Questionnaire); HADS (Hospital Anxiety & Depression Score); EQ-5D (EuroQol EQ-5D
questionnaire); DINE (Dietary Instrument for Nutrition Education); GSE (General Self Efficacy); IMD (Indices of Multiple Deprivation)
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physical activity [47], anxiety and depression [48], quality
of life [49], dietary habits [50] and self-efficacy [51] using
validated questionnaires that were self-completed by par-
ticipants, as outlined in Table 4. Ambulatory activity was
measured using a CW-700 Yamax Digi-Walker electronic
pedometer with a 7-day memory (Yamax Corporation,
Tokyo, Japan) and an average step count per day was cal-
culated from measurements from at least 3 days.
Follow-up data collection
The control and intervention groups will be recalled at 6
months and 12 months for repeat measurements (Table 4).
All persons involved in the collection of follow-up data will
be independent and blinded to study group allocation.
Feasibility and acceptability Acceptability of the
TRIMS education programme will be measured by
obtaining qualitative feedback. Possible topics to be
explored include ease of understanding; views about the
content of the programme and style of delivery; and
usefulness and relevance (including cultural relevance).
An independent researcher will conduct semi-structured
interviews via the telephone. Information about the
interviews and a reply slip will be given in person or
posted to participants who attend the education
sessions. Purposive sampling will be used to select a
demographically varied sample of subjects to be inter-
viewed from those who volunteer. Written consent will
be obtained in advance by post and confirmed verbally
at the time of the interview. Feasibility will be assessed
through identification and consideration of problems
encountered during implementation of the intervention
and uptake will be measured by comparing the number
of responses to the number of invitations.
Sample size The TRIMS study is powered to detect a
between group difference of 30% in the proportion of
people with prevalent MetS at 12 months (prevalence of
MetS reduced to 60% in the intervention group and 90%
in controls, alpha = 0.05, power = 0.80) and allowing
20% for loss to follow up, 80 participants were required
in total, 40 people in each of the control and interven-
tion arms. The power calculation was based on the
results of the Oslo Diet and Exercise Study (ODES)[52]
which achieved a difference of 55% between the diet
and exercise group and the control group. With our less
intensive group lifestyle programme a more modest dif-
ference of 30% was assumed.
Data analysis Continuous outcome variables were tested
for normality and independent-sample t-tests or Mann
Table 5 The International Diabetes Federation (IDF) and updated National Cholesterol Education Panel (NCEP)
definitions of metabolic syndrome.
NCEP (2005)[37] IDF (2005)[6]
ESSENTIAL REQUIREMENT
Central obesity
Waist circumference
>94 cm
† (males)
>80 cm
† (females)
ANY 3 out of the following 5
↓
+ ANY 2 out of the following 4
↓
1) Raised fasting plasma glucose:
≥ 5.6 mmol/l*
1) Raised fasting plasma glucose:
≥ 5.6 mmol/l
2) Raised triglycerides:**
≥ 1.7 mmol/l
and/or
3) Low HDL cholesterol:**
< 1.03 (males)
< 1.29 (females)
2) Raised triglycerides:
≥ 1.7 mmol/l
(or specific treatment for)
and/or
3) Reduced HDL cholesterol
< 1.03 (males)
< 1.29 (females),
(or specific treatment for)
4) Hypertension:**
Blood pressure ≥ 130/85 mmHg
4) Raised blood pressure:
Blood pressure ≥ 130/85 mmHg
(or treatment for previously
diagnosed hypertension)
5) Central obesity:
Waist circumference
> 102 cm (males)
> 88 cm (females)
Updated from the original NCEP 2001 definition [5]:
*previous fasting plasma glucose value (≥6.1 mmol/l)
was updated to include a lower value;
** was updated to include drug treatment .
†Waist circumference ethnic-specific for Europid men & women; Waist circumference for South
Asians (Chinese, Malay, & Asian Indian): ≥90 cm (males), & ≥80 cm (females).
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Page 8 of 16Whitney-U tests were used to compare between group dif-
ferences at baseline; chi-square tests were used to compare
categorical variables. Baseline data entry was conducted
blind to group assignment, and steps were taken to ensure
that data analysis was blinded as far as possible. Analysis
of follow-up data will be conducted on an intention to
treat basis. The study groups will be compared with
respect to proportions of subjects with MetS at 12 months
using the chi-squared test, followed by logistic regression
modelling to adjust for any substantial chance imbalance
between the groups, including adjustments for gender and
ethnicity. Further study outcomes will be compared using
similar methods and linear modelling, as appropriate and
95% confidence intervals will be calculated for treatment
effects, corresponding to the statistical testing. Significance
will be assessed at the 5% level. PASW Statistics version
18.0 (SPSS Inc.) will be used to conduct all statistical ana-
lyses. Qualitative feedback collected in order to gauge the
acceptability of the TRIMS programme will be analysed
using a thematic approach including the use of charting
[40] to collate the data.
Results
Participants were recruited to the main trial between
November 2009 and July 2010 (Figure 1). In total, 322
potentially eligible people were invited to participate
from 8 different general practices. Of those people who
were invited, 40% (n = 129) volunteered to participate,
1 6 %( n=5 2 )r e f u s e d ,a n d4 4 %( n=1 4 1 )d i dn o tr e p l y .
Reasons given by those who declined to participate (n =
52) included lack of time due to work or other commit-
ments (23%), no perceived need for additional advice or
health checks (29%), and other health problems (5%).
Overall, 82 people were enrolled onto the study, 42 to
the intervention group and 40 to the control.
Table 6 shows the key characteristics for the overall
study population and by treatment group. The randomi-
sation procedure led to balanced samples in the interven-
tion and control groups, with no statistically significant
differences in the demographic or clinical characteristics
between the study arms. Of the 82 participants, 36 (44%)
were male, 18 (22%) were of SA ethnicity, median age
was 63 years (IQR 57 - 67), mean waist size 106 cm (SD
±11), BMI 30 kg/m
2 (IQR 28 - 33), 10 (12%) were current
smokers, and 42 (51%) of participants were prescribed a
statin and 42 (51%) an anti-hypertensive.
According to pedometer measurements, the median
number of steps/day for participants was 5762 (IQR
3365 - 8592). Self-reported time spent sitting was 300
mins/day (IQR 180 - 360). Dietary data indicated that
46% (n = 34) of people were classified as having a low
fibre intake and 15% (n = 11) as having a high fat
intake. The median number of portions of fruit, salad
and vegetables consumed per day was 3 (IQR 2 - 4).
All participants had MetS according to the IDF defini-
tion: 31% (n = 25) met 3 criteria, 54% (n = 44) met 4
criteria, and 16% (n = 13) met 5 criteria. The MetS
values for the individual criteria for BP, HDL and trigly-
cerides were met by 80 - 90% of people. However, only
22 participants (27%), 12 (29%) intervention and 10
(25%) control, met the criterion for raised fasting plasma
glucose. Overall, the prevalence of MetS according to
the updated NCEP criteria[37] was 94% (n = 77), 93%
(n = 39) intervention group and 95% (n = 38) control
(p = 1.000).
Table 7 and Table 8 present the main variables related
to MetS, according to gender and ethnicity respectively.
Characteristics for most variables across the treatment
groups showed no significant differences. However,
mean waist size was smaller for females in the interven-
tion (99 cm, SD ±11) versus the control (106 cm, SD
±12), borderline statistical significance (p = 0.055).
According to ethnicity, HDL levels were significantly
higher for WEs in the intervention versus the control
(1.3 mmol/l, IQR 1.1 - 1.8, v.s 1.2 mmol/l, IQR 1.1 - 1.3,
p = 0.015) and triglycerides levels were lower
(1.4 mmol/l, IQR 0.8 - 1.9, v.s 1.7 mmol/l, IQR 1.4 -
2.2) although statistical significance was borderline
(p = 0.053).
Discussion
As far as we are aware, the TRIMS study is the first
RCT in the UK to investigate the delivery of a lifestyle
intervention to people with MetS to improve CVD and
diabetes risk factors. More, specifically, we have devel-
oped an evidence based structured group education pro-
gramme and aim to determine the impact of attending
the education programme on features of MetS and qual-
ity of life after 12 months of follow-up.
Existing evidence from clinical trials is limited regard-
ing the effectiveness of strategies aimed at primary pre-
vention of T2DM and/or CVD in people with MetS.
However, an RCT conducted in Italy in people with
MetS demonstrated that an intervention promoting a
Mediterranean style diet significantly reduced the preva-
lence of MetS after 2 years of follow-up compared to the
control group [53]. Findings from another Italian study
with 1 year of follow-up suggest that a lifestyle interven-
tion focusing on nutrition and physical activity is effec-
tive in both reversing MetS and reducing the incidence
of diabetes [54]. Additionally, a recent sub-group analysis
of a larger RCT in a Norwegian population, found that a
combined diet and exercise intervention in people with
MetS significantly reduced the prevalence of MetS at 1
year follow-up compared to the control group [52].
Further evidence from secondary data analyses of two
large diabetes prevention programmes, the Diabetes Pre-
vention Program (DPP) in the US and the Finish Diabetes
Dunkley et al. Trials 2011, 12:107
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style intervention focused on weight loss and exercise
significantly reduces the prevalence of MetS [55,56]. In
the DPP, lifestyle was compared to both placebo and
metformin [55] and in the DPS lifestyle was compared to
usual care [56]. However, the populations studied were
highly selected, in that all had impaired glucose tolerance.
Research is needed into the effectiveness of lifestyle pro-
grammes for primary prevention of T2DM and CVD in
mixed-ethnic populations with MetS. The TRIMS pro-
gramme was developed as a pragmatic early intervention
that can be easily implemented to a large number of peo-
ple in primary care.
Results from the analysis of baseline data indicate that
the randomisation procedure led to balanced samples
between the study arms, with no statistically significant
differences in the characteristics between the overall inter-
vention and control groups. When the main variables
Refusals 
n = 52 
Volunteers 
n = 129 
Letter of invitation 
mailed in batches to 
eligible people 
n = 322
Reply slips received 
n = 181
Attended 
BASELINE 
assessment 
n = 106 
Randomised 
n = 82 
Withdrawn 
n = 24 
Excluded not eligible n = 22 
 Withdrew consent prior to randomisation n = 2 
INTERVENTION 
n = 42 
CONTROL
n = 40 
Withdrawn 
n = 23 
Excluded not eligible n = 12 
 Did not attend > 3 times  n = 3 
Unable to contact or changed mind n = 3 
Unable to make dates left n = 3 
Volunteers not contacted n = 2 
Figure 1 Flow chart of recruitment and randomisation to TRIMS Study.
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Page 10 of 16Table 6 Key baseline characteristics of participants for all individuals and by study group
Characteristics n All
(n = 82)
n Intervention
(n = 42)
n Control
(n = 40)
p value
(I vs. C)
Demographic characteristics
Age (yrs) 82 63 [57 - 67] 42 65 [55 - 68] 40 62 [58 - 67] p = 0.831
Sex: Male 82 36 (43.9) 42 21 (50.0) 40 15 (37.5) p = 0.359
Ethnicity: 82 42 40 p = 0.268
South Asian 18 (22.0) 11 (26.2) 7 (17.5)
White 62 (75.6) 31 (73.8) 31 (77.5)
Other 2 (2.4) 0 (0.0) 2 (5.0)
IMD score (2007) 82 19.50 [14.04 - 33.74] 42 21.49 [14.04 - 21.49] 40 18.59 [13.55 - 32.96] p = 0.344
NS-SEC-5 class: 82 42 40 p = 0.708
1 17 (20.7) 9 (21.4) 8 (20.0)
2 19 (23.2) 7 (16.7) 12 (30.0)
3 10 (12.2) 6 (14.3) 4 (10.0)
4 15 (18.3) 8 (19.0) 7 (17.5)
5 21 (25.6) 12 (28.6) 9 (22.5)
Measures related to MetS
Waist circumference(cm) 82 105.5 ± 10.8 42 103.9 ± 10.2 40 107.2 ± 11.2 p = 0.161
Systolic BP (mmHg) 82 132.4 ± 15.4 42 134.9 ± 13.2 40 129.8 ± 17.3 p = 0.139
Diastolic BP (mmHg) 82 85.9 ± 9.5 42 85.6 ± 9.7 40 86.1 ± 9.5 p = 0.803
HDL cholesterol (mmol/l) 82 1.20 [1.00 - 1.50] 42 1.20 [1.00 - 1.53] 40 1.20 [1.03 - 1.48] p = 0.367
Triglycerides(mmol/l) 82 1.60 [1.20 - 2.00] 42 1.45 [0.98 - 1.93] 40 1.60 [1.40 - 2.08] p = 0.112
FPG (mmol/l) 82 5.21 ± 0.56 42 5.23 ± 0.44 40 5.19 ± 0.66 p = 0.714
Proportion meeting IDF criteria for:
BP 82 73 (89.0) 42 37 (88.1) 40 36 (90.0) p = 1.000
FPG 82 22 (26.8) 42 12 (28.6) 40 10 (25.0) p = 0.908
HDL 82 72 (87.8) 42 35 (83.3) 40 37 (92.5) p = 0.313
Triglycerides 82 67 (81.7) 42 35 (83.3) 40 32 (80.0) p = 0.917
Total n° of IDF criteria met: 82 42 40 p = 0.924
3 25 (30.5) 13 (31.0) 12 (30.0)
4 44 (53.7) 23 (54.8) 21 (52.5)
5 13 (15.9) 6 (14.3) 7 (17.5)
Other bio-medical measures
BMI (kg/m
2) 82 30.2 [28.1 - 33.1] 42 29.3 [27.8 - 32.2] 40 30.9 [28.8 - 34.1] p = 0.140
Total cholesterol (mmol/l) 82 4.99 ± 0.86 42 4.82 ± 0.77 40 5.17 ± 0.93 p = 0.067
LDL cholesterol (mmol/l) 80 2.92 ± 0.74 42 2.80 ± 0.68 38 3.05 ± 0.80 p = 0.126
HbA1c (mmol/l) 80 42.0 [40.0 - 43.0] 40 41.0 [39.0 - 42.8] 40 42.5 [40.0 - 44.0] p = 0.179
2 hour glucose (mmol/l) 81 5.80 ± 1.65 41 5.65 ± 1.43 40 5.95 ± 1.85 p = 0.419
Lifestyle & well being
Current smoker: yes 82 10 (12.2) 42 4 (9.5) 40 6 (15.0) p = 0.514
Fruit & vegetables (portions/day) 82 3.0 [2.0 - 4.0] 42 3.0 [2.0 - 4.0] 40 3.0 [2.0 - 5.0] p = 0.429
Pedometer counts (av steps/day) 72 5762 [3365 - 8592] 39 6829 [3224 - 8596] 33 4774 [3522 - 8653] p = 0.705
EQ-5D score 82 0.80 [0.72 - 1.00] 42 0.80 [0.73 - 1.00] 40 0.76 [0.69 - 1.00] p = 0.293
EQ-5D VAS 81 80.0 [70.0 - 90.0] 41 80.0 [70.0 - 90.0] 40 80.0 [ 61.3 - 90.8] p = 0.420
Parametric continuous data are expressed as mean ± S.D; nonparametric continuous data as median [IQR]; categorical data as number (%).
Other ethnicity category: 1 Caribbean Indian, 1 mixed Caribbean/White British. NS-SEC-5 class: 1 (Managerial & professional occupations); 2 (Intermediate
occupations); 3 (Small employers & own account workers); 4 (Lower supervisory & technical occupations); 5 (Semi-routine & routine occupations).
IMD score: greater scores indicate a higher level of deprivation.
Abbreviations: IMD (Index of Multiple Deprivation); NS-SEC (National Statistics Socio-economic Classification); BP (blood pressure); HDL (high density lipoprotein
cholesterol); FPG (fasting plasma glucose); IDF (International Diabetes Federation); BMI (body mass index); LDL (low density lipoprotein ); HbA1c (glycated
haemoglobin); EQ-5D (EuroQol EQ-5D); VAS (visual analogue scale).
Dunkley et al. Trials 2011, 12:107
http://www.trialsjournal.com/content/12/1/107
Page 11 of 16Table 7 Measures related to metabolic syndrome by gender
Metabolic syndrome components All Intervention Control p value
(I vs. C)
Male, (n = 36) Female, (n = 46) Male, (n = 21) Female, (n = 21) Male, (n = 15) Female, (n = 25) Male, Female
Waist circumference(cm) 109.0 ± 8.7 102.8 ± 11.5 108.5 ± 7.6 99.2 ± 10.5 109.6 ± 10.3 105.8 ± 11.7 p = 0.669 p = 0.055
Systolic BP (mmHg) 134.9 ± 13.7 130.5 ± 16.6 135.3 ± 11.7 134.4 ± 14.8 134.3 ± 16.6 127.2 ± 17.5 p = 0.822 p = 0.140
Diastolic BP (mmHg) 86.3 ± 9.6 85.5 ± 9.6 86.1 ± 10.6 85.1 ± 9.0 86.6 ± 8.4 85.8 ± 10.2 p = 0.890 p = 0.783
HDL cholesterol (mmol/l) 1.15 [1.00 - 1.40] 1.20 [1.10 - 1.50] 1.20 [1.00 - 1.40] 1.30 [1.10 - 1.80] 1.10 [0.90 - 1.50] 1.20 [1.10 - 1.45] p = 0.528 p = 0.238
Triglycerides (mmol/l) 1.50 [1.05 - 2.10] 1.60 [1.20 - 2.00] 1.40 [0.90 - 2.10] 1.60 [1.00 - 1.80] 1.60 [1.20 - 2.20] 1.70 [1.40 - 2.10] p = 0.541 p = 0.116
FPG (mmol/l) 5.29 ± 0.53 5.15 ± 0.57 5.36 ± 0.47 5.11 ± 0.38 5.19 ± 0.61 5.19 ± 0.70 p = 0.339 p = 0.611
Proportion meeting IDF criteria for:
BP 31 (86.1) 42 (91.3) 17 (81.0) 20 (95.2) 14 (93.3) 22 (88.0) p = 0.376 p = 0.614
FPG 11 (30.6) 11 (23.9) 8 (38.1) 4 (19.0) 3 (20.0) 7 (28.0) p = 0.295 p = 0.717
HDL 29 (80.6) 43 (93.5) 16 (76.2) 19 (90.5) 13 (86.7) 24 (96.0) p = 0.674 p = 0.585
Triglycerides 32 (88.9) 35 (76.1) 18 (85.7) 17 (81.0) 14 (93.3) 18 (72.0) p = 0.626 p = 0.717
Total no of IDF criteria met:
3 12 (33.3) 13 (28.3) 8 (38.1) 5 (23.8) 4 (26.7) 8 (32.0) p = 0.903 p = 0.636
4 17 (47.2) 27 (58.7) 9 (42.9) 14 (66.7) 8 (53.3) 13 (52.0)
5 7 (19.4) 6 (13.0) 4 (19.0) 2 (9.5) 3 (20.0) 4 (16.0)
Parametric continuous data are expressed as mean ± S.D; nonparametric continuous data as median [IQR]; categorical data as number (%).
BP (blood pressure); HDL (high density lipoprotein); FPG (fasting plasma glucose); IDF (International Diabetes Federation).
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6Table 8 Measures related to metabolic syndrome by ethnicity (South Asian and white European only*)
Metabolic syndrome components All Intervention Control p value
(I vs. C)
SA, (n = 18) WE, (n = 62) SA, (n = 11) WE, (n = 31) SA, (n = 7) WE, (n = 31) SA WE
Waist circumference(cm) 101.6 ± 10.6 106.8 ± 10.8 101.6 ± 8.4 104.7 ± 10.8 101.6 ± 14.1 109.0 ± 10.5 p = 0.989 p = 0.118
Systolic BP (mmHg) 135.2 ± 16.8 132.0 ± 15.1 137.6 ± 15.4 133.9 ± 12.4 131.3 ± 19.4 130.1 ± 17.5 p = 0.452 p = 0.326
Diastolic BP (mmHg) 90.2 ± 9.7 84.8 ± 9.3 92.6 ± 8.1 83.1 ± 9.1 86.6 ± 11.5 86.4 ± 9.3 p = 0.213 p = 0.163
HDL cholesterol (mmol/l) 1.20 [0.98 - 1.43] 1.20 [1.08 - 1.43] 1.10 [0.90 - 1.20] 1.30 [1.10 - 1.80] 1.30 [1.20 - 1.60] 1.20 [1.10 - 1.30] p = 0.082 p = 0.015
Triglycerides (mmol/l) 1.65 [1.20 - 1.95] 1.60 [1.10 - 2.03] 1.70 [1.20 - 2.10] 1.40 [0.80 - 1.90] 1.60 [1.40 - 1.90] 1.70 [1.40 - 2.20] p = 0.784 p = 0.053
FPG (mmol/l) 5.29 ± 0.60 5.20 ± 0.55 5.20 ± 0.49 5.25 ± 0.43 5.43 ± 0.77 5.15 ± 0.65 p = 0.450 p = 0.480
Proportion meeting IDF criteria for:
BP 15 (83.3) 56 (90.3) 9 (81.8) 28 (90.3) 6 (85.7) 28 (90.3) p = 1.000 p = 1.000
FPG 5 (27.8) 17 (27.4) 3 (27.3) 9 (29.0) 2 (28.6) 8 (25.8) p = 1.000 p = 1.000
HDL 14 (77.8) 56 (90.3) 8 (72.7) 27 (87.1) 6 (85.7) 29 (93.5) p = 1.000 p = 0.671
Triglycerides 13 (72.2) 52 (83.9) 7 (63.6) 28 (90.3) 6 (85.7) 24 (77.4) p = 0.596 p = 0.300
Total no of IDF criteria met:
3 8 (44.4) 17 (27.4) 6 (54.5) 7 (22.6) 2 (28.6) 10 (32.3) p = 0.446 p = 0.670
4 9 (50.0) 33 (53.2) 5 (45.5) 18 (58.1) 4(57.1) 15 (48.4)
5 1 (5.6) 12 (19.4) 0 (00.0) 6 (19.4) 1 (14.3) 6 (19.4)
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6related to MetS were compared separately by ethnicity and
gender, one variable showed a significant difference
between the intervention and control group, and two were
of borderline statistical significance. However, these obser-
vations should not be over interpreted; as significance was
assessed at the 5% level, some statistical differences might
have been expected by chance due to the number of vari-
ables compared.
We acknowledge that our intervention is less intensive
than the diet and exercise intervention in the ODES trial
[52], on which our power calculation is based. However,
our intervention is pragmatic and designed to be appro-
priate to be delivered in the “real world setting”.A d d i -
tionally, we are not looking for a difference of 55% as
found in the ODES trial but a more modest difference of
30% between our intervention and control groups. We
consider that the intensity of our intervention is sufficient
to justify using resolution of MetS as the primary out-
come. Furthermore, evidence from our random effects
meta-analysis we conducted suggests that lifestyle advice
(diet and/or exercise) is effective for reversing MetS (OR
4.15, 95% CI 3.92-4.39) [31].
Additionally, if the prevalence of MetS is in the region of
30% [13], one-to-one counselling is unlikely to be feasible
in a primary care setting. A previous study, conducted by
our research group in people with impaired glucose toler-
a n c e( P R E P A R E )[ 2 7 ]w a sf o u n dt ob ev e r ye f f e c t i v ea t
improving glycaemic control and increasing physical activ-
ity (in particular walking) alongside only 3 hours of con-
tact time. We have taken a pragmatic approach and
developed a group based education programme, with a
written evidence based curriculum, underpinned with
appropriate learning and health-behaviour theories, and
providing 6 hours of contact time.
Around half of all participants were prescribed a statin
and/or antihypertensive at b a s e l i n e .H o w e v e r ,t h i sw a s
similar for both intervention and control group partici-
pants. We acknowledge that compliance could change
during the study period but this could be a possible bene-
fit of the intervention. In addition, it is recognised that
prescribing may change, including new prescriptions for
lipid or blood pressure medication to those who were
medication naïve at baseline. This would then result in
no change in the appropriate MetS criterion. However,
prescribing changes will occur in a “real world setting”
and are likely to occur in both groups. We are recording
prescription medications at baseline, 6 months and 12
months and we will also consider looking at prescription
records at the end of the study. Furthermore, our
planned analysis using multi-variable regression methods
will allow us to consider adjustment for prescribed
medication.
We recognise that the majority of previous epidemio-
logical studies and clinical trials have used the NCEP
definition [5,37] to identify MetS. However, bearing in
mind the ethnic diversity in our study population, provi-
sion of ethnic-specific cut-off points for waist circumfer-
ence and central obesity within the IDF definition [6]
led to preferential selection of this definition for our
trial. Additionally, secondary outcome measures for the
s t u d yi n c l u d et h ep r e v a l e n c eo fM e t Sa c c o r d i n gt o
NCEP criteria at 12 months follow-up compared to
baseline.
We acknowledge that our study excluded people who
were unable to understand, speak and read English.
However, our study population includes a subset of the
SA population in the UK (English speaking people
mainly of Indian origin), and overall 22% of participants
were of SA ethnicity. Additionally, we took steps to
address cultural needs, for example by including foods
commonly eaten in the SA community. If the education
programme is found to be successful we will consider
adapting it for non-English speakers and ethnically
diverse populations. However, we acknowledge that
additional work would need to be conducted to test for
transferability of the intervention to other settings and
populations.
Conclusions
As far as we are aware, the TRIMS study is the first
RCT in the UK to investigate the delivery of a struc-
tured group education programme to individuals with
MetS to improve management of cardiovascular and
diabetes risk factors. Follow-up data will be collected at
6 and 12 months. Results will provide important evi-
dence to help inform primary prevention strategies for
diabetes and CVD in high risk individuals, in a multi-
ethnic population.
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